Study of DS9051b for adrenal cancer and prostate cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced adrenal cancer or metastatic prostate cancer that has not responded to prior treatments.
- You must be in generally good health (able to do light activities or be up and about).
- Your liver, kidneys, and bone marrow must work well enough based on blood tests.
- You cannot have certain untreated brain tumors or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
This trial tests a combination of two experimental drugs, HS-20093 and HRS-5041, for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if this new treatment can help control the cancer when other treatments have stopped working.
This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.